Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ACACA | Q13085 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14280360 | 0.84 | ACLY (0.31) | TSHRALDH1A1CYP2C19ACLYCYP2D6 | |
| SCHEMBL13212714 | 0.80 | TSHR (0.44) | TSHRALDH1A1CYP2C19CYP2D6HIF1A | |
| SCHEMBL12050476 | 0.78 | TSHR (0.33) | TSHRALDH1A1CYP2C19ACLYCYP2D6 | |
| SCHEMBL11214932 | 0.78 | ALDH1A1 (0.33) | ALDH1A1CYP2C19POLBBLMATM | |
| SCHEMBL8310580 | 0.78 | TSHR (0.33) | TSHRALDH1A1CYP2C19ACLYCYP2D6 | |
| SCHEMBL7339999 | 0.76 | TSHR (0.33) | TSHRALDH1A1CYP2C19CYP2D6HIF1A | |
| SCHEMBL12710486 | 0.76 | — | — | |
| SCHEMBL8609242 | 0.76 | TSHR (0.40) | TSHRALDH1A1CYP2C19ACLYCYP2D6 | |
| SCHEMBL15120370 | 0.75 | DGAT1 (0.35) | ALDH1A1CYP2C19POLBBLMATM | |
| SCHEMBL23352052 | 0.75 | CYP2C19 (0.46) | TSHRCYP2C19CYP2D6BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-04 | — | — | US | disclosed |
| EP-0903346-A1 | SYDNONE IMINE DERIVATIVES | Chugai Seiyaku Kabushiki Kaisha (JP) | 1999-03-24 | — | — | EP | disclosed |
| EP-0640594-A1 | Hydantoin derivative as metalloprotease inhibitor | FUJIREBIO INC. (JP) | 1995-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, PYGL | TSHR 4103/4885ALDH1A1 1615/4885CYP2C19 689/4885 |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | HCCS, HAVCR2, NR1H4 | TSHR 3525/4885ALDH1A1 1584/4885CYP2C19 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.